Alimera Sciences: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
The newest statements on file are more than two years old.
Your own DCF model
A full discounted-cash-flow model of Alimera Sciences, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst its own history
Alimera Sciences's multiples at each month end with a market cap on file, Jan 2020 to Jan 2024, each against its own median.
Price to sales
3.9×Now above its median of 0.6×, in the top quarter of its range; range 0.3× to 3.9× over 6 months.
As of Jan 5, 2024
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2023to Dec 31, 2023 | $81 M | $-20 M | $-14 M | $0 M | $-15 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $54 M | $-18 M | $-10 M | $0 M | $-10 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $59 M | $-4 M | $-3 M | $1 M | $-4 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $51 M | $-5 M | $-2 M | $1 M | $-3 M | — | SEC annual report (10-K, 20-F) |
| FY2019to Dec 31, 2019 | $54 M | $-10 M | $-4 M | $0 M | $-4 M | $33 M | SEC annual report (10-K, 20-F) |
| FY2018to Dec 31, 2018 | $47 M | $-16 M | $-12 M | $0 M | $-12 M | $27 M | SEC annual report (10-K, 20-F) |